Feasibility and Tolerability of Chemoimmunotherapy Given During Induction for Treatment of Patients With High-Risk Neuroblastoma: A Report From the Children's Oncology Group
Journal of Clinical Oncology · 03.11.2026
DOI: 10.1200/jco-26-00810 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, online erschienen am 03.11.2026. Verfasst von Sara M Federico und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, St Jude Children's Research Hospital, Memphis, TN. Die Arbeit nennt 20 Literaturangaben. Gefördert von: NCI NIH HHS.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Purpose
The addition of the anti-GD2 antibody dinutuximab (DIN) to postconsolidation therapy led to improved event-free survival (EFS) for patients with high-risk neuroblastoma (HRNBL). The combination of DIN with chemotherapy (chemoimmunotherapy) results in objective responses in patients with recurrent/refractory neuroblastoma. We evaluated the feasibility of administering chemoimmunotherapy during induction for HRNBL in a multicenter trial.
Methods
Children's Oncology Group (COG) ANBL17P1 was a prospective, single-arm, limited institution pilot study to assess tolerability and feasibility of administering DIN and sargramostim with induction chemotherapy cycles 3-5. The primary end point of tolerability was assessed as the occurrence of a predefined unacceptable toxicity or toxic death during DIN-containing cycles. Feasibility was assessed as ability to receive ≥75% of planned DIN doses. Revised International Neuroblastoma Response Criteria were used to assess response.
Results
Forty eligible, evaluable patients with newly diagnosed HRNBL were enrolled at eight sites from January 2019 to June 2020. The most common DIN-related grade ≥3 toxicities during induction cycles 3-5 included fever (30.0%) and pain (7.5%). There were no unacceptable toxicities or toxic deaths during induction cycles 3-5. Patients received 92.0%-101.8% of intended induction DIN doses. This regimen was therefore deemed both feasible and tolerable. Thirty-seven patients completed all end-of-induction evaluations; 13 had complete response (CR), 22 partial response (PR), one minor response (MR), zero stable disease, and one progressive disease. The overall end of induction CR + PR rate was 87.5%. The 3-year EFS was 52.5% ± 7.9%.
Conclusion
Administration of DIN with COG induction cycles 3-5 for patients with newly diagnosed HRNBL was tolerable and feasible. This approach is currently being evaluated in a COG randomized phase III trial.
Autor:innen und Institutionen
- Department of Oncology, St Jude Children's Research Hospital, Memphis, TN.
- Department of Pediatrics, Children's Oncology Group Statistics and Data Center, University of Florida, Gainesville, FL.
- Children's Oncology Group Statistics and Data Center, Monrovia, CA.
- Department of Pediatrics and Carbone Cancer Center, University of Wisconsin, Madison, WI.
- Department of Radiation Oncology, University of California at San Francisco, UCSF Benioff Children's Hospital, San Francisco, CA.
- Department of Radiation Oncology, St Jude Children's Research Hospital, Memphis, TN.
ORCID-Profile: Sara M Federico, Arlene Naranjo, Fan F Zhang, Paul Sondel, Megan Lilley, Steve Braunstein, Christopher Tinkle, Hiroyuki Shimada, Meredith S Irwin, Alice L Yu, Araz Marachelian, Shahab Asgharzadeh, Ami V Desai, Jason Jarzembowski, Daphne Haas-Kogan, Tamarah J Westmoreland, Marguerite T Parisi, Barry Shulkin, Wayne Furman, Steven G DuBois, Rochelle Bagatell, Julie R Park, Suzanne Shusterman
Förderung
- NCI NIH HHS
Zitieren
APA
Federico, S. M., Naranjo, A., Zhang, F. F., Sondel, P., Shahi, A., Lilley, M., Braunstein, S., Tinkle, C., Yanik, G., Shimada, H., Irwin, M. S., Yu, A. L., Marachelian, A., Asgharzadeh, S., Desai, A. V., Jarzembowski, J., Haas-Kogan, D., Westmoreland, T. J., Parisi, M. T., …, & Shusterman, S. (2026). Feasibility and Tolerability of Chemoimmunotherapy Given During Induction for Treatment of Patients With High-Risk Neuroblastoma: A Report From the Children's Oncology Group. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-00810
Vancouver
Federico SM, Naranjo A, Zhang FF, Sondel P, Shahi A, Lilley M, et al. Feasibility and Tolerability of Chemoimmunotherapy Given During Induction for Treatment of Patients With High-Risk Neuroblastoma: A Report From the Children's Oncology Group. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-00810
BibTeX
@article{Federico2026,
author = {Federico, Sara M and Naranjo, Arlene and Zhang, Fan F and Sondel, Paul and Shahi, Ankita and Lilley, Megan and Braunstein, Steve and Tinkle, Christopher and Yanik, Gregory and Shimada, Hiroyuki and Irwin, Meredith S and Yu, Alice L and Marachelian, Araz and Asgharzadeh, Shahab and Desai, Ami V and Jarzembowski, Jason and Haas-Kogan, Daphne and Westmoreland, Tamarah J and Parisi, Marguerite T and Shulkin, Barry and Acord, Michael and Furman, Wayne and DuBois, Steven G and Bagatell, Rochelle and Park, Julie R and Shusterman, Suzanne},
title = {Feasibility and Tolerability of Chemoimmunotherapy Given During Induction for Treatment of Patients With High-Risk Neuroblastoma: A Report From the Children's Oncology Group},
journal = {Journal of Clinical Oncology},
year = {2026},
doi = {10.1200/jco-26-00810}
}
EUVIMED